Peide Biopharma Completes Tens of Millions of RMB Series A Financing to Advance AI-Driven Peptide Drug Pipeline

Source: Shell Finance

Beijing News Shell Finance News: On December 19, according to the WeChat Official Account of "PDBio," Chengdu PDBio Co. Ltd. ("PDBio"), which focuses on peptide drug research and development, announced the completion of a multi-million yuan Series A round of financing. This round of financing was exclusively invested by the Shannuo Fund under Shenzhen Qianhai Shangshan Jinshi Private Equity Investment Fund Management Co. Ltd. The funds raised will be used to advance the core pipeline research and development for pain, cardiovascular, cerebrovascular, and respiratory diseases, while also deploying large-scale artificial intelligence (AI)-assisted peptide drug development technology.